DrugComb - an integrative cancer drug combination data portal

Bulat Zagidullin1,†, Jehad Aldahdooh1,†, Shuyu Zheng1, Wenyu Wang1, Yinyin Wang1, Joseph Saad1, Alina Malyutina1, Alberto Pessia1 and Jing Tang1,2,3,*.

1Institute for Molecular Medicine Finland, Helsinki Life Science Institute, University of Helsinki, Finland
2Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Finland
3Department of Mathematics and Statistics, University of Turku, Finland
*To whom correspondence should be addressed. Email: jing.tang@helsinki.fi
†Joint First Authors. The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.

ABSTRACT
Drug combination therapy has the potential to enhance efficacy, reduce dose-dependent toxicity and prevent the emergence of drug resistance. However, discovery of synergistic and effective drug combinations has been a laborious and often serendipitous process. In recent years, identification of combination therapies has been accelerated due to the advances in high-throughput drug screening, but informatics approaches for systems-level data management and analysis are needed. To contribute toward this goal, we created an open-access data portal (https://drugcomb.fimm.fi) where the results of drug combination screening studies are accumulated, standardized and harmonized. Through the data portal, we provided the web server to analyze and visualize users’ own drug combination screening data. The users have an option to upload their data to DrugComb, as part of a crowdsourcing data curation effort. To initiate the data repository, we collected 437,932 drug combinations tested on a variety of cancer cell lines. We showed that linear regression approaches, when considering chemical fingerprints as predictors, have the potential to achieve high accuracy of predicting the sensitivity and synergy of drug combinations. All the data and informatics tools are freely available in DrugComb to enable a more efficient utilization of data resources for future drug combination discovery.

INTRODUCTION
The current cancer treatment is still largely based on a “one size fits all” approach, resulting in limited efficacy due to the heterogeneity between the patients. Molecular diagnostics, histopathology and imaging techniques help stratify and monitor patients, but they provide limited support to guide treatment selection, especially for patients with recurrent cancers. NGS (Next Generation Sequencing) technologies and other omics profiling have revealed the intrinsic heterogeneity in cancer, partly explaining why patients respond differently to the same therapy (1). Even when there is an initial treatment response, cancer cells can easily develop drug resistance by the emerging activation of compensating or bypassing pathways (2). To reach effective and sustained clinical responses, many cancer patients who become resistant to standard treatments urgently need new multi-targeted drug combinations, which can effectively inhibit the cancer cells and block the emergence of drug resistance, while selectively incurring minimal effects on healthy cells (3). Although many new drugs are being developed, there is little information to guide the selection of
effective combinations, as well as the identification of patients that would benefit from such combinatorial therapies. Recently, high-throughput drug combination screening techniques have been successfully applied for the functional testing of cancer cell lines or patient-derived samples, with several important hits being made (4). However, the exponentially increasing number of possible drug combinations makes a pure experimental approach quickly unfeasible, even with automated drug screening instruments (5). Therefore, data integration approaches to predict and annotate the drug combination effects at the systems level becomes a necessary route (6). To guide the patient stratification, biomarker discovery and treatment selection, a number of data harmonization, standardization and modelling challenges need to be solved before the promise of personalized drug combinations is ultimately met (7,8).

To help achieve these goals, we present DrugComb (https://drugcomb.fimm.fi/), a web-based data portal that aims to harmonize and standardize drug combination screen data for cancer cell lines. In particular, we focused on the common experimental designs where drug pairs were crossed at different doses, forming a dose-response matrix. We provided tools via a web server that allow users to visualize, analyze and annotate such dose-response data. These tools can be used for the determination of drug combination sensitivity and synergy. In addition, we provided the visualization of dose-response matrices as well as single drug response curves. Furthermore, to facilitate a crowdsourcing effort, we provided data submission tools to encourage users to share and redistribute their data in a standardized manner. Through the web server, we established a data curation pipeline to collect datasets from several major drug combination studies, covering 437,923 drug combination experiments with 7,423,800 data points across 93 human cancer cell lines. We provided the sensitivity and synergy scores for these drug combinations, and showed that these scores can be predicted by linear regression models using the structural information of the compounds. The mechanisms of action of drug combinations can be further illustrated from drug-target interaction profiles provided by major pharmacology databases including STITCH (9), PubChem (10) and ChEMBL (11). The harmonized DrugComb data can be readily linked with genomic, transcriptomic and proteomic profiles of the cancer cells, which are available in major cancer cell line databases such as COSMIC (12), CTRP (13) and MCLP (14).

DrugComb is designed to be a major source of information relevant to drug combination research, as there is currently lack of open-access services and repositories containing harmonized results of drug combinations studies. Furthermore, the analysis of drug combinations, especially in terms of their efficacy and synergy, as well as their mechanisms of action, were largely missing. With the help of data curation and analysis tools provided by DrugComb, we expect that the users may benefit from such efforts and be willing to form a community with a critical mass, so that more datasets can be collectively curated and centrally deposited. Ultimately, such a drug combination community shall lead to a consensus on the essential information that is needed to conform to the FAIR principle of research data (15). Furthermore, we expect that DrugComb will make an ideal testbed for more advanced machine learning algorithms to predict and prioritize the most effective drug combinations,
which may ultimately lead to a cost-effective treatment decision support tool for the rational design of drug combinations. DrugComb prioritizes collection and dissemination of high-quality data related to drug combinations, so as to enable better understanding, validation, and prediction of synergistic drug combinations for individual cancer patients. This one-stop workflow proposed by DrugComb makes it a unique tool in cancer drug discovery research.

In this manuscript, we describe major components of DrugComb, including a web server with a variety of data analysis tools, as well as a database repository including a pipeline of how the curation and standardization of the major drug combination studies were done. Such a pipeline can be further developed into a protocol that may be adopted by a wider drug combination screen community. Furthermore, we report the initial results of the drug combination prediction as a case study, and highlight the potential of machine learning techniques to improve the efficiency of drug combination discovery. To facilitate the use of web server and the interpretation of the data analysis results, a step-by-step user guide is also provided in the Supplementary Information and will be kept up-to-date in the web site. Future aspects of DrugComb development are also discussed in Conclusions.

DATA PORTAL COMPONENTS
The DrugComb data portal includes two major components, the web server and the database (Figure 1). The web server, mainly available at the Analysis page (https://drugcomb.fimm.fi/analysis/), consists of modules that generate the numeric and graphical results of drug combination sensitivity and synergy analyses for users’ proprietary data. The database, retrievable at the Home page, harbors the curated datasets and their analysis results that are publicly accessible. To facilitate the annotation of these drug combinations, we utilized third party APIs to access i) chemical-protein association networks in the STITCH database, ii) molecular structural information in the PubChem database and iii) ligand-based target predictions in the ChEMBL database. A registered user may also submit the proprietary data via the Contribution page (https://drugcomb.fimm.fi/contribute/), which will be evaluated by the administrator for its appropriateness to be deposited in the database. All the data visualization functionalities are built using Javascript. Computational backend employs MariaDB for the database, while R, Python and PHP routines are used for the drug combination sensitivity and synergy analyses.

Computational Tools
We designed, developed and integrated a set of tools that facilitate the data processing and analysis tasks in drug combination screening research. A user needs to upload an input file that should contain information about the compounds and the cell lines, including names, concentrations and drug effects in the unit of percentage of inhibition (% inhibition) of cancer cells. Furthermore, a unique identifier, termed block id, is needed to differentiate the same drug combinations that are repeated in multiple batches, as well as serve as a unique identifier for each of the drug pairs tested. The output of the web server consists of sensitivity and synergy scores that are summarized in a table which can be further linked to more detailed graphical results. For example, the drug combination sensitivity score
(CSS) is determined as the average area under the combinations’ dose-response curves with one compound fixed at the IC\textsubscript{50} concentration (Unpublished material https://www.biorxiv.org/content/10.1101/512244v1, Supplementary Information). CSS summarizes the dose-responses of a drug combination screen using a metric of % inhibition, which could then be readily compared to its monotherapy drug sensitivity scores, such as DSS (16) or AAC (17). The difference between CSS and the maximal DSS of the two constitute drugs, termed as S score, is used to evaluate the benefits of a drug combination. On the other hand, to assess the degree of drug-drug interactions, also known as drug combination synergy, we provided reference models to determine the expected effect of non-interaction. Currently four commonly-used reference models were utilized, including Bliss independence (BLISS), Highest single agent (HSA), Loewe additivity (LOEWE), and Zero interaction potency (ZIP) (18-20). When two drugs are administered together their combined effect could be greater, identical or less than that predicted by their individual potencies. This is referred to as drug synergy, drug additivity or drug antagonism respectively (21). The drug combination synergy scores were then determined as the difference between the observation and expectation, with higher values being more synergistic than lower values. As these four models are based on a distinctive set of empirical or biological assumptions, which might lead to different quantification of the degree of interaction, we therefore provided all of them for users’ discretion (22). The web server also generates graphical results, including the drug combination response and synergy landscapes over the dose matrix, the monotherapy dose-response curves of its constituent drugs, and the box plots of CSS and S scores (Figure 2). The computational engine of the web server is extended from the R package synergyfinder (23), while the details on the analytical methods can be found in Supplementary Information.

**DATABASE CONTENT**

DrugComb aims at free access to standardized drug screening results. Utilizing the computational tools that are available on the web server, we managed to collect and curate drug combination screen data involving 2276 drugs tested in 437,932 combinations for 93 cancer cell lines from 10 different tissues. The sources of the data include: i) The NCI ALMANAC dataset (24), ii) The ONEIL dataset (25), iii) The FORCINA dataset (26) and iv) The CLOUD dataset (27) (Table 1). To make the datasets comparable, we standardized the % viability values, determined as the ratio between the counts for cells treated with drugs and cells treated with DMSO as negative control, measured at the end time point. The drug effects were then represented as % inhibition values, defined as 100 - % viability. The data curation aims to determine a full dose-response matrix where the monotherapy and combination doses were matched. More specifically, in the ALMANAC dataset screenings have been performed in two different stages using two different protocols. In the first stage drugs were screened in single doses on the full NCI60 cell panel to efficiently capture compounds with anti-proliferative activity. Compounds with above threshold effects were subsequently screened in the 5-dose panel. Two different screening protocols in the second stage resulted in dose-response matrices of 6x4 and 4x4 shapes. For the ONEIL dataset the cell viability was measured as the ratio of the exponential growth rate for cells treated with a drug versus DMSO. The experiment was designed so that the monotherapy and the drug combinations were tested separately. However, the concentrations that
were tested in the monotherapy screen were not identical to those in the combination screen. We thus utilized the four-parameter logistic model, available in the R drc package (28), to estimate the monotherapy responses at the concentrations tested in the combination screen. For the Forcina dataset, the % viability values were determined using the cell counts at the time of 96 hours, even though the data for other intermediate time points were also available. For the CLOUD dataset, we fitted a 4-parameter log-logistic model similar for the ONEIL dataset to estimate the % inhibition values for those drug combinations for which the single drug effects were not reported.

For the curated drug combinations, DrugComb reported the analysis results provided by the computational tools as described earlier. Furthermore, multiple views on their annotations from other databases were also made directly available. For example, STITCH can provide a network-centric view on the drug-target interactions for a drug combination, while ChEMBL and PubChem can provide the most up-to-date information on their potential mechanisms of actions and signaling pathways, which can be further validated using experimental techniques, such as CRISPR-Cas9 or RNAi genetic screens (29,30). We provided flexible query options to navigate the repository of harmonized drug combination data and their analysis results, which may encourage users to contribute their own screening results, thus promoting a community-driven ecosystem for data sharing and redistribution. A data contribution module (https://drugcomb.fimm.fi/contribute/) is therefore provided to allow users to upload their curated datasets for which the reporting of sufficient information on the experimental procedures is mandatory.

WEB SERVER IMPLEMENTATION
To start the DrugComb pipeline, a comma-separated values (csv) file compliant with a specific format needs to be uploaded. An example of such is provided in the Analysis page to facilitate the file generating. The server will generate the analysis outputs in two panels: Table and Graph. The Table panel is the default option which provides information about combined drugs, cell lines in which the combinations are tested, CSS as well as synergy scores determined using different reference models. The graphical results are displayed under the Graph panel, which can be activated after selecting a drug combination in the Table panel. This Graph panel contains three tabs: Sensitivity, Synergy and Annotation. The Sensitivity tab provides the results on drug combination sensitivity, including CSS-S plot, color-coded %inhibition values over the dose-response matrix, as well as monotherapy dose-response curves for the two constitute drugs. The Synergy tab contains drug combination synergy landscapes determined by the four reference models, with colour code and visualization options similar to that in the Sensitivity tab. Available only when their chemical identifiers are available, the Annotation tab contains information on the putative mechanisms of action obtained from the third-party databases including STITCH, PubChem and ChEMBL. STITCH provides drug-target interactions using evidence from experiments, databases and literature. PubChem is queried for the structural information of the drugs and ChEMBL is queried for the predicted drug targets based on the structural similarity. Predicted targets, if available, are given for each of the compounds separately. Information shown in the Annotation panel should allow for further exploration of the drug-target space in a network-centric view for a selected drug combination.
DrugComb is built using PHP 7.2.11 for server-side data processing, Javascript ECMAScript 2015 for the frontend and Plotly library 1.40.0 for the generation of the interactive visualizations. Data is stored in MariaDB 10.1.37 with RMariaDB 1.0.6.9000 as the driver for interfacing with R. Software development tools including Python 3.6.7, numpy 1.14.1, pandas 0.23.4, scikit-learn 0.20.2, RDkit 2018.03.4, R version 3.5.1, synergyfinder 1.8.0 and tidyverse 1.2.1 are used in the analytical pipelines. Linux distribution CentOS-7 with the kernel 3.10.0 64-bit running on four processor cores and 64 Gb of RAM is used for hosting the web service on the in-house computational cluster. API-based access to PubChem is performed according to (https://pubchemdocs.ncbi.nlm.nih.gov/pug-rest), to STITCH using (https://www.stitchdata.com/docs/stitch-connect/api), and ChEMBL using (https://www.ebi.ac.uk/chembl/api/data/docs).

CASE STUDIES
Here we present three case studies that have been performed on the curated data in DrugComb. The first case study involved a descriptive analysis of the dataset, where drugs and cell lines were clustered according to their mechanisms of action and tissue of origin. The second case study aimed to analyze the reproducibility of drug combination screen data. This was done via the comparison of the CSS values of replicates found across and within the study sources. The third case study employed linear regression to predict the CSS values using chemical descriptors of the drug molecules, demonstrating the potential of machine learning methods.

Annotations of drugs and cell lines
To retrieve the mechanisms of actions of the 2,276 drugs in DrugComb, their chemical identifiers were queried from major databases including STITCH, PubCHEM, ChEMBL, DrugBank (31) and KEGG (32). These identifiers were then used for retrieving the pharmacological action information that is available in these databases. We followed the compound classification used in ChEMBL to manually determine the mechanism type, yielding the following categories with their proportions: inhibitor (28.09%), receptor (18.34%), blocker (2.98%), antagonist (2.54%), modulator (0.83%), agonist (0.79%) and activator (0.22%) (Figure 3A). In addition, 12.21% of drugs have been labeled as ‘other’ as their mechanisms of action are not common enough to be placed in new categories. Notably, the remaining 33.22% of drugs do not have well-documented mechanisms of action and hence have been labeled as ‘unknown’. To understand the mechanisms of action of these drug combinations, it becomes imperative to obtain more information on their unannotated constituent compounds. For example, MK-4541 was found in 5,772 combinations across six cancer tissues, while its pharmacology information remains unknown in those major databases. We did a literature survey and found that MK-4541 has been reported to selectively modulate androgen receptor (AR), acting as an AR agonist (33). Therefore, we expected that more compounds may be annotated similarly by searching the literature which has yet been curated. A more systematic annotation may be achieved via the DrugTargetCommons platform (https://drugtargetcommons.fimm.fi/), where the crowdsourcing efforts are utilized for extracting quantitative bioactivity values of drug-target interactions from the literature (34). For the 93 cancer cell lines, their annotations have been obtained from the Cellosaurus database (35) to determine their tissues of origin. All together 10 distinct tissues were present with
lung cancer (16.13%), ovary cancer (15.05%) and skin cancer (15.05%) being the most common ones (Figure 3B). It can be seen that all the major cancer tissue types except for liver and stomach cancers are well represented in DrugComb, and thus demonstrating the general relevance of the existing data.

Reproducibility of drug combination screens

Experimental reproducibility, in particular levels of interlaboratory concordance in the drug response phenotypes has been reported to be an issue in cancer drug screening (36). Since DrugComb aims to provide standardized results of drug combination screens, assessment of inter- and intra-study data reproducibility is of high importance. The reproducibility was evaluated using standard deviation (sd) of CSS values, which is determined for each unique drug pair and cell line combination. We chose to evaluate the CSS reproducibility as CSS indicates the average % inhibition of a drug combination and therefore makes the replicates comparable even though they were done in different concentrations. Altogether 34,936 drug-pair-cell-line combinations were replicated, while the majority of them were found either from only within the ONEIL study (n = 22,133) or from only within the ALMANAC study (n = 11,915). In contrast, the number of replicated drug combinations across the ONEIL and the ALMANAC studies is relatively few (n = 604). On the other hand, the drug combinations that were tested in the FORCINA and the CLOUD studies were not replicated, as FORCINA and CLOUD involve single cell lines of T98G and KBM-7 separately, that were not tested elsewhere. The average sd for within-study replicates is 4.25 and 12.02 for ONEIL and ALMANAC respectively, both of which are smaller than that (average sd 15.44) for their between-study replicates (p < 10^{-30}, wilcoxon rank-sum test, Figure 4). The higher reproducibility of ONEIL compared to ALMANAC is expected, as the ONEIL study consisted of a standardized experiment design that involves only technical replicates while the ALMANAC study collected data from multiple labs that differed in their experimental designs, and therefore represents biological replicates in different batches (Table 1). On the other hand, for each of the n = 604 drug-pair-cell-line combinations that were replicated between ONEIL and ALMANAC, we fixed the drug-pair and picked up randomly one cell line from ONEIL and one cell line from ALMANAC, and considered the sd of the CSS values as the negative control for the between-study reproducibility. The average sd for such ‘negative control’ replicates is 17.5 which is significantly higher (p < 10^{-4}, wilcoxon signed-rank paired test), suggesting a satisfactory reproducibility of the between-study replicates (Figure 4).

Prediction accuracy of drug combination sensitivity

In this case study we aimed to evaluate the prediction accuracy of machine learning algorithms on the drug combination data. We considered the fingerprint information of the drug combinations as the predictors and utilized the root mean squared error (RMSE) to evaluate the prediction accuracy. To generate the fingerprint vectors for a drug combination, canonical SMILES for the constituent drugs were obtained from PubChem and then were converted to 2048 fingerprint bits using Rdkit python module (version 2018.03.4), where each bit corresponds to the presence or absence of a particular structural feature. The drug combination fingerprints were generated using the bitwise averaging of
the single drug fingerprints (37). More specifically, the presence of a structural feature in both drugs yields 2 in the combination fingerprint, while presence only in one yields 1 and lack in both yields 0. These 3-bit arrays were then used as features in the machine learning algorithms. For each cell line, we fit a linear regression model on the 80% of drug combinations using a nested cross-validation and then test its prediction accuracy on the remaining 20% data. As a control, we utilized an additive model to predict CSS, which is the sum of average %inhibition from the two single drugs. The use of such an additive model was to reflect the baseline prediction assuming that the average %inhibition of a drug combination is simply the sum of their individual drug effects.

As shown in Figure 5, we found that the prediction accuracy is higher for the linear regression model than the additive model across all the tissue types, suggesting that the drug combination fingerprints carry predictive features for explaining the sensitivity. However, all the tissues exhibited multi-modality in the distribution of RMSE, suggesting a cell-line or drug-combination level heterogeneity of prediction accuracies. As a future step more advanced non-linear machine learning methods such as deep learning may be tested (38). Furthermore, molecular information of the cell lines may worth exploring for the discovery of predictive biomarkers for drug combinations.

**COMPARISON TO EXISTING DATA PORTALS**

To the best of our knowledge, the existing data portals that cover partially drug combination screen data analysis and collection included DeepSynergy (http://shiny.bioinf.jku.at/DeepSynergy/), DrugCommbdb (http://drugcommbdb.denglab.org) (unpublished, https://www.biorxiv.org/content/10.1101/477547v2) and SynergyFinder (https://synergyfinder.fimm.fi/) (39). DeepSynergy provides a deep learning machine learning model that was trained on the ONEIL data and has been shown to predict new drug combinations with superior accuracy compared to conventional machine learning approaches. However, DeepSynergy did not provide the web service for the sensitivity and synergy analyses of the drug combination screen data. Furthermore, the deep learning model was trained only with the ONEIL dataset, and thus may become suboptimal when predicting a drug combination in an untested cell line. DrugCommbdb is a database that harbors the concurrent screening data for 105k drug combinations. While the dataset has been collected via deep curation, it has not been analyzed with the drug combination sensitivity and synergy tools either. Therefore, both DeepSynergy and DrugCommbdb provided limited web-server functionality to analyze drug combination screen data. In contrast, DrugComb provided the web-server that builds on our recent informatics approaches to assess both the sensitivity and synergy level of drug combinations, and therefore may potentially help the interpretations of the DrugCommbdb data as well as contributing to the training data that is needed for DeepSynergy and other advanced machine learning models.

SynergyFinder is our recent web application for the drug combination screen data analysis. However, the focus of SynergyFinder is to analyze the degree of interactions in a drug combination screen, while the functionality of analyzing the sensitivity of drug combinations is missing. Furthermore, SynergyFinder does not provide the data curation and annotation functionality. In contrast, DrugComb provides the functionality of both a web-server and a database that have become integral components for establishing a major portal for drug combination data standardization and harmonization. Taken
together, DrugComb is well positioned to provide complementary resources that can be connected with these existing tools for a more systematic and more community-driven effort for future drug combination development.

**CONCLUSIONS**
How to make cancer treatment more personalized and more effective remains one of the grand challenges in the healthcare system. Drug combinations may provide enhanced efficacy to combat the cancer drug resistance and therefore may provide more sustainable treatment options for the patients. To accelerate the discovery of personalized multi-targeted drug combinations, knowledge-bases to curate, annotate and interpret the drug combination screen data are needed. The DrugComb portal provides free-access web server to analyze high-throughput drug combination screen data and thus makes it possible to develop a community-driven data repository that allows for the testing of machine learning algorithms. Future efforts include the collection of molecular profiles for cancer cell lines such that more predictive features may be extracted from the cellular genetic or epigenetic context. This may lead to the identification of biomarkers which can be used to stratify the patients for a rational selection of drug combinations. On the other hand, the curated drug combination screen data may also help define more accurate cancer cell dependency models (https://depmap.org). Furthermore, efficient statistical methods need to be developed for evaluating the significance of drug combination experimental data, which shall demonstrate that the drug combination predictions can be translated into treatment suggestions. In the long run, the DrugComb data portal is expected to provide widely applicable informatics tools to predict, test and understand drug combinations, not only for cancer cell lines but also for patient-derived samples that may lead to novel, more effective and safe treatments compared to the current cytotoxic and single-targeted therapies.

**AVAILABILITY**
All the code used in generation of 3 case studies is available on github (https://github.com/netphar/first_pub)

**SUPPLEMENTARY DATA**
Supplementary Data is available as a separate file and under Help section on https://drugcomb.fimm.fi

**AUTHOR CONTRIBUTIONS**
JT, BZ and JA designed the study. JT and BZ wrote the manuscript. JA engineered the web server. BZ, SZ, WW, WW, YW, JS, AM, AP performed data analysis.

**ACKNOWLEDGEMENT**
We thank the authors of the ALAMANC, ONEIL, FORCINA and CLOUD studies for making their drug combination data fully accessible.

**FUNDING**
This work was supported by the European Research Council (ERC) starting grant agreement DrugComb [grant number 716063], Academy of Finland grant [grant number 317680], China Scholarship Council grant, Finland's EDUFI Fellowship. Funding for open access charge is provided by the European Research Council (ERC) starting grant agreement DrugComb [grant number 716063].

CONFLICT OF INTEREST
None declared.

REFERENCES:
1. Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A., Golub, T.R., Meyerson, M., Gabriel, S.B., Lander, E.S. and Getz, G. (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature, 505, 495-501.
http://www.ncbi.nlm.nih.gov/pubmed/24390350
http://dx.doi.org/10.1038/nature12912
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048962

2. Gottesman, M.M., Lavi, O., Hall, M.D. and Gillet, J.P. (2016) Toward a Better Understanding of the Complexity of Cancer Drug Resistance. Annual review of pharmacology and toxicology, 56, 85-102.
http://www.ncbi.nlm.nih.gov/pubmed/26514196
http://dx.doi.org/10.1146/annurev-pharmtox-010715-103111

3. Hanahan, D. (2014) Rethinking the war on cancer. Lancet (London, England), 383, 558-563.
http://www.ncbi.nlm.nih.gov/pubmed/24351321
http://dx.doi.org/10.1016/s0140-6736(13)62226-6

4. Crystal, A.S., Shaw, A.T., Sequist, L.V., Fréboulet, L., Niederst, M.J., Lockerman, E.L., Frías, R.L., Gainor, J.F., Amzallag, A., Greninger, P. et al. (2014) Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science (New York, N.Y.), 346, 1480-1486.
http://www.ncbi.nlm.nih.gov/pubmed/25394791
http://dx.doi.org/10.1126/science.1254721
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388482

5. Tang, J. and Altokallio, T. (2014) Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles. Current pharmaceutical design, 20, 23-36.
http://www.ncbi.nlm.nih.gov/pubmed/23530504

6. Lord, C.J., Tutt, A.N. and Ashworth, A. (2015) Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annual review of medicine, 66, 455-470.
http://www.ncbi.nlm.nih.gov/pubmed/25341009
http://dx.doi.org/10.1146/annurev-med-050913-022545

7. Tang, J. (2017) Informatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations. Methods in molecular biology (Clifton, N.J.), 1636, 485-506.
http://www.ncbi.nlm.nih.gov/pubmed/28730498
http://dx.doi.org/10.1007/978-1-4939-7154-1_30
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322649

8. Scarlett, U.K., Chang, D.C., Murtagh, T.J. and Flaherty, K.T. (2016) High-Throughput Testing of Novel-Novel Combination Therapies for Cancer: An Idea Whose Time Has Come. Cancer discovery, 6, 956-962.
http://www.ncbi.nlm.nih.gov/pubmed/27587468
9. Szklarczyk, D., Santos, A., von Mering, C., Jensen, L.J., Bork, P. and Kuhn, M. (2016) STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. *Nucleic acids research*, 44, D380-384.

10. Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B.A., Thiessen, P.A., Yu, B. *et al.* (2019) PubChem 2019 update: improved access to chemical data. *Nucl. acids research*, 47, D1102-D1109.

11. Gaulton, A., Hersey, A., Nowotka, M., Bento, A.P., Chambers, J., Mendez, D., Mutwo, P., Atkinson, F., Bellis, L.J., Cibrian-Uhalte, E. *et al.* (2017) The ChEMBL database in 2017. *Nucleic acids research*, 45, D945-D954.

12. Tate, J.G., Bamford, S., Jubb, H.C., Sondka, Z., Beare, D.M., Bindal, N., Boutselakis, H., Cole, C.G., Creature, C., Dawson, E. *et al.* (2019) COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic acids research*, 47, D941-D947.

13. Seashore-Ludlow, B., Rees, M.G., Cheah, J.H., Cokol, M., Price, E.V., Coletti, M.E., Jones, V., Bodycombe, N.E., Soule, C.K., Gould, J. *et al.* (2015) Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. *Cancer discovery*, 5, 1210-1223.

14. Li, J., Zhao, W., Akbani, R., Liu, W., Ju, Z., Ling, S., Vellano, C.P., Roebuck, P., Yu, Q., Eterovic, A.K. *et al.* (2017) Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. *Cancer cell*, 31, 225-239.

15. Wilkinson, M.D., Dumontier, M., Aalbersberg, I.J., Appleton, G., Axton, M., Baak, A., Blomberg, N., Boiten, J.W., da Silva Santos, L.B., Bourne, P.E. *et al.* (2016) The FAIR Guiding Principles for scientific data management and stewardship. *Scientific data*, 3, 160018.

16. Yadav, B., Pemovska, T., Szewc, A., Kulesskiy, E., Kontro, M., Karjalainen, R., Majumder, M.M., Malani, D., Murumagi, A., Knowles, J. *et al.* (2014) Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. *Scientific reports*, 4, 5193.
17. Yang, W., Soares, J., Greninger, P., Edelman, E.J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J.A., Thompson, I.R. et al. (2013) Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic acids research, 41, D955-961.
   http://www.ncbi.nlm.nih.gov/pubmed/23180760
   http://dx.doi.org/10.1093/nar/gks1111
   http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531057

18. Berenbaum, M.C. (1989) What is synergy? Pharmacological reviews, 41, 93-141.
   http://www.ncbi.nlm.nih.gov/pubmed/2692037

19. Loewe, S. (1953) The problem of synergism and antagonism of combined drugs. Arzneimittel-Forschung, 3, 285-290.
   http://www.ncbi.nlm.nih.gov/pubmed/13081480

20. Yadav, B., Wennerberg, K., Aittokallio, T. and Tang, J. (2015) Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model. Computational and structural biotechnology journal, 13, 504-513.
   http://www.ncbi.nlm.nih.gov/pubmed/26949479
   http://dx.doi.org/10.1016/j.csbj.2015.09.001
   http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759128

21. Tallarida, R.J. (2011) Quantitative methods for assessing drug synergism. Genes & cancer, 2, 1003-1008.
   http://www.ncbi.nlm.nih.gov/pubmed/22737266
   http://dx.doi.org/10.1177/1947601912440575
   http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379564

22. Tang, J., Wennerberg, K. and Aittokallio, T. (2015) What is synergy? The Saariselka agreement revisited. Frontiers in pharmacology, 6, 181.
   http://www.ncbi.nlm.nih.gov/pubmed/26388771
   http://dx.doi.org/10.3389/fphar.2015.00181
   http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555011

23. He, L., Kulesskiy, E., Saarela, J., Turunen, L., Wennerberg, K., Aittokallio, T. and Tang, J. (2018) Methods for High-throughput Drug Combination Screening and Synergy Scoring. Methods in molecular biology (Clifton, N.J.), 1711, 351-398.
   http://www.ncbi.nlm.nih.gov/pubmed/29344898
   http://dx.doi.org/10.1007/978-1-4939-7493-1_17

24. Holbeck, S.L., Camalier, R., Crowell, J.A., Govindharajulu, J.P., Hollingshead, M., Anderson, L.W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D. et al. (2017) The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. Cancer research, 77, 3564-3576.
   http://www.ncbi.nlm.nih.gov/pubmed/28446463
   http://dx.doi.org/10.1158/0008-5472.Can-17-0489
   http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499996

25. O’Neil, J., Benita, Y., Feldman, I., Chenard, M., Roberts, B., Liu, Y., Li, J., Kral, A., Lejnine, S., Loboda, A. et al. (2016) An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies. Molecular cancer therapeutics, 15, 1155-1162.
   http://www.ncbi.nlm.nih.gov/pubmed/26983881
   http://dx.doi.org/10.1158/1535-7163.Mct-15-0843

26. Forcina, G.C., Conlon, M., Wells, A., Cao, J.Y. and Dixon, S.J. (2017) Systematic Quantification of Population Cell Death Kinetics in Mammalian Cells. Cell systems, 4, 600-610 e606.
   http://www.ncbi.nlm.nih.gov/pubmed/28601558
   http://dx.doi.org/10.1016/j.cels.2017.05.002
   http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509363
27. Licciardello, M.P., Ringler, A., Markt, P., Klepsch, F., Lardeau, C.H., Sdelci, S., Schirghuber, E., Muller, A.C., Caldera, M., Wagner, A.  
et al. (2017) A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor. Nature chemical biology,  
13, 771-778.  
http://www.ncbi.nlm.nih.gov/pubmed/28530711  
http://dx.doi.org/10.1038/nchembio.2382

28. Ritz, C., Baty, F., Streibig, J.C. and Gerhard, D. (2015) Dose-Response Analysis Using R.  
PloS one, 10, e0146021.  
http://www.ncbi.nlm.nih.gov/pubmed/26717316  
http://dx.doi.org/10.1371/journal.pone.0146021  
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696819

29. Han, K., Jeng, E.E., Hess, G.T., Morgens, D.W., Li, A. and Bassik, M.C. (2017) Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nature biotechnology, 35, 463-474.  
http://www.ncbi.nlm.nih.gov/pubmed/28319085  
http://dx.doi.org/10.1038/nbt.3834  
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557292

30. Boettcher, M., Tian, R., Blau, J.A., Markegard, E., Wagner, R.T., Wu, D., Mo, X., Biton, A., Zaitlen, N., Fu, H.  
et al. (2018) Dual gene activation and knockout screen reveals directional dependencies in genetic networks. Nature biotechnology; 36, 170-178.  
http://www.ncbi.nlm.nih.gov/pubmed/29334369  
http://dx.doi.org/10.1038/nbt.4062  
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072461

31. Wishart, D.S., Feunang, Y.D., Guo, A.C., Lo, E.J., Marcu, A., Grant, J.R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z.  
et al. (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic acids research, 46, D1074-D1082.  
http://www.ncbi.nlm.nih.gov/pubmed/29126136  
http://dx.doi.org/10.1093/nar/gkx1037  
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753335

32. Kanehisa, M., Sato, Y., Furumichi, M., Morishima, K. and Tanabe, M. (2019) New approach for understanding genome variations in KEGG. Nucleic acids research, 47, D590-D595.  
http://www.ncbi.nlm.nih.gov/pubmed/30321428  
http://dx.doi.org/10.1093/nar/gky962  
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324070

33. Chisamore, M.J., Gentile, M.A., Dillon, G.M., Baran, M., Gambone, C., Riley, S., Schmidt, A., Flores, O., Wilkinson, H. and Alves, S.E. (2016) A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice. The Journal of steroid biochemistry and molecular biology, 163, 88-97.  
http://www.ncbi.nlm.nih.gov/pubmed/27106747  
http://dx.doi.org/10.1016/j.jsbmb.2016.04.007

34. Tang, J., Tanoli, Z.U., Ravikumar, B., Alam, Z., Rebane, A., Vaha-Koskela, M., Peddinti, G., van Adrichem, A.J., Wakkenen, J., Jaiswal, A.  
et al. (2018) Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions. Cell chemical biology, 25, 224-229 e222.  
http://www.ncbi.nlm.nih.gov/pubmed/29276046  
http://dx.doi.org/10.1016/j.chembiol.2017.11.009  
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814751

35. Bairoch, A. (2018) The Cellosaurus, a Cell-Line Knowledge Resource. Journal of biomolecular techniques : JBT, 29, 25-38.  
http://www.ncbi.nlm.nih.gov/pubmed/29805321  
http://dx.doi.org/10.7171/jbt.18-2902-002
36. Hatzis, C., Bedard, P.L., Birkbak, N.J., Beck, A.H., Aerts, H.J., Stem, D.F., Shi, L., Clarke, R., Quackenbush, J. and Haibe-Kains, B. (2014) Enhancing reproducibility in cancer drug screening: how do we move forward? *Cancer research*, 74, 4016-4023.

http://www.ncbi.nlm.nih.gov/pubmed/25015668
http://dx.doi.org/10.1158/0008-5472.Can-14-0725
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119520

37. Mason, D.J., Stott, I., Ashenden, S., Weinstein, Z.B., Karakoc, I., Meral, S., Kuru, N., Bender, A. and Cokol, M. (2017) Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure. *Journal of medicinal chemistry*, 60, 3902-3912.

http://www.ncbi.nlm.nih.gov/pubmed/28383902
http://dx.doi.org/10.1021/acs.jmedchem.7b00204

38. Preuer, K., Lewis, R.P.I., Hochreiter, S., Bender, A., Bulusu, K.C. and Klambauer, G. (2018) DeepSynergy: predicting anti-cancer drug synergy with Deep Learning. *Bioinformatics (Oxford, England)*, 34, 1538-1546.

http://www.ncbi.nlm.nih.gov/pubmed/29253077
http://dx.doi.org/10.1093/bioinformatics/btx806
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925774

39. Ianevski, A., He, L., Aittokallio, T. and Tang, J. (2017) SynergyFinder: a web application for analyzing drug combination dose-response matrix data. *Bioinformatics (Oxford, England)*, 33, 2413-2415.

http://www.ncbi.nlm.nih.gov/pubmed/28379339
http://dx.doi.org/10.1093/bioinformatics/btx162
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554616

**TABLE AND FIGURES LEGENDS**
Figure 1. Overview of DrugComb portal and the workflow. Drug combination screen data can be uploaded by users or from the literature. Data curation includes harmonization of drug effects as percentage inhibitions compared to the DMSO negative control, and determination of drug combination sensitivity (CSS and S scores) and synergy scores (HSA, Bliss, Loewe and ZIP scores). All harmonized data and their analysis results are stored in MariaDB with regular backups, which can be visualized into dose-response curves and matrices, as well as synergy landscapes. External tools allow for network-centric representation of drug-drug interactions from STITCH database, skeletal views of drug molecules for PubChem, as well as predicted drug-target interactions from ChEMBL database.

Figure 2. Examples of the web server analysis results, demonstrating the MK-4827 and Bortezomib combination in the MSTO cell line. (A) Single and combination dose-responses graphs, as well as the CSS-S boxplots. (B) Drug synergy landscapes determined using the HSA, Bliss, Loewe and ZIP reference models. For both panels values are colour-coded such that green corresponds to lower values and red corresponds to higher values. (C) Representation of drug-target network for the selected drug combination obtained from the STITCH database. (D) Skeletal formulae of the queried compounds from PubChem. (E) Drug-target predictions from ChEMBL.
Figure 3. Classification of drugs and cell lines in DrugComb. Drugs were classified according to the mechanism types, following the ChEMBL implementation. Cell lines were classified according to the tissue of origin.

Figure 4. Replicability of drug combinations between and within studies represented as the distribution of the standard deviations of the Drug combination sensitivity scores (CSS). Mean values for each of the kernel density plots are delineated with a dotted line of corresponding color.
Figure 5. Performance of predicting CSS using linear regression as compared to the additive model. The RMSE for each cell line was grouped as density plots according to its tissue type. Dashed lines within each plot indicate interquartile range of the distribution.

Table 1. The data statistics of the four studies curated in DrugComb.

| Study    | Number of drugs | Number of drug combinations | Number of cell lines | Number of tissues | Size of the full dose-response matrix |
|----------|-----------------|-----------------------------|----------------------|-------------------|--------------------------------------|
| ALMANAC  | 103             | 303,737                     | 60                   | 10                | 4x4 or 6x4                           |
| ONEIL    | 38              | 92,208                      | 39                   | 6                 | 5x5                                  |
| FORCINA  | 1,818           | 1,818                       | 1                    | 1                 | 2x2                                  |
| CLOUD    | 283             | 40,160                      | 1                    | 1                 | 2x2                                  |